Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

Fig. 3

Among patients with KRAS wild-type tumors, those with high SLFN11 expression had significantly longer survival than patients with low SLFN11-expressing ones (Log rank P = 0.048) (a). However, among patients with mutated KRAS tumors, those with high SLFN11 expression had almost the same survival as patients with low SLFN11-expressing ones(Log rank P = 0.709) (b)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us